Should Mounjaro users stay at 5mg longer? What the data says

What's this video probably claiming?

Based on the caption, @sarah_with_pcos is likely arguing that patients on tirzepatide 5mg should resist the urge to escalate to 7.5mg, framing this as a science-backed position. She's probably referencing a graph shared by @TheFamilyChemist showing dose-response data, possibly suggesting that weight loss or side effect profiles at 5mg are competitive enough with higher doses to make escalation unnecessary for some patients. Given her PCOS context, she may also be touching on tolerability, hormonal benefits, or insulin sensitivity improvements that appear at lower doses. The affiliate code in the caption is worth flagging upfront: she has a financial relationship with The Family Chemist, a UK-based pharmacy. That doesn't automatically invalidate her claims, but it means you should look at the graph she's referencing with some skepticism about how it's been framed or cherry-picked.

What does the science actually show?

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) is the reference point here. At 72 weeks, mean weight loss was 15.0% at 5mg, 19.5% at 10mg, and 20.9% at 15mg. So yes, 5mg produces meaningful weight loss, but the dose-response relationship is real and statistically significant between 5mg and higher doses. The gap between 5mg and 10mg is larger than most social media posts acknowledge. A separate analysis of SURMOUNT-1 showed that gastrointestinal adverse events, primarily nausea, vomiting, and diarrhea, were dose-dependent: 5mg patients reported GI events in roughly 71% of cases versus 78-80% at higher doses. That's a narrower tolerability gap than people expect. For PCOS specifically, no large randomized controlled trials have compared tirzepatide doses head-to-head on hormonal outcomes, so any dose-specific claims about PCOS benefits beyond weight loss are extrapolated, not proven.

Where does the social media noise diverge from clinical reality?

The "stay at 5mg" narrative online tends to conflate two separate questions: what's the minimum effective dose for weight loss, and what's the optimal dose for a given individual. These aren't the same thing. A patient who loses 10% body weight at 5mg and feels well is not the same as a patient who loses 5% and has hit a plateau. Social media flattens that distinction entirely. There's also a recurring misreading of the SURMOUNT data where people focus on absolute weight loss numbers without acknowledging baseline BMI differences across dose groups or the role of titration timing. The 5mg dose in SURMOUNT was a maintenance dose after titration, not a starting dose held indefinitely, which changes the interpretation significantly. Graphs shared by pharmacies promoting their own products, even accurate ones, have an obvious selection incentive. Whether the graph @TheFamilyChemist provided shows the full SURMOUNT dose-response curve or a curated slice of it matters enormously to the conclusion being drawn.

What should you actually know?

Tirzepatide dose decisions should be made between a patient and their prescriber based on individual response, tolerability, and clinical goals, not TikTok graphs. That said, there is legitimate clinical nuance here. Some patients do reach adequate weight loss responses at 5mg and have no clinical reason to escalate. The SURMOUNT protocol itself allowed dose escalation to be paused if tolerability was a concern, which suggests the prescribing framework already accommodates this. For people with PCOS, weight loss of any meaningful amount has documented benefits for menstrual regularity and androgen levels (Teede et al., 2023, Nature Medicine), but there is no dose-specific PCOS evidence for tirzepatide yet. If you're on 5mg and your prescriber agrees you're responding well, staying there is a reasonable clinical decision. If you're not hitting your goals, staying at 5mg because a TikToker with an affiliate code said so is not a good reason. Talk to your prescriber.